Renalytix plc

("Renalytix" or the "Company")

Cancellation of Ordinary Shares

Total Voting Rights

LONDON and NEW YORK, 6 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, following the Placing and Subscription undertaken by the Company which was announced on 30 September 2024 (the "Fundraising Announcement"), one of the subscribers is limiting his Subscription in the Fundraise to £281,955, which is 2,422,723 shares or £218,045 short of his allocated amount. In addition, 8,877 shares have not been settled with an accounts payable and debt holder which equates to £798.93.

Cancellation of Ordinary Shares and Total Voting Rights

The Company will therefore cancel 2,431,600 Ordinary Shares at or around 8.00 am tomorrow, 7 November 2024 (the "Cancellation").

Following the Cancellation, the issued share capital of the Company will consist of 331,206,012 Ordinary Shares. Each Ordinary Share carries one vote and there are no shares held in treasury. Therefore, the total number of voting rights in the Company following Cancellation tomorrow will be 331,206,012 and this figure may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change of their interest in the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Capitalised terms used in this announcement have the meanings given to them in the Fundraising Announcement, unless the context provides otherwise.

The person responsible for making this Announcement on behalf of the Company is James McCullough, Chief Executive Officer.

For further information, please contact:

About Renalytix plc

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.